Articles Vol. 67 No. 5 25/05/2026

EVALUATION OF EMPIRICAL ANTIBIOTIC TREATMENT OUTCOMES IN PATIENTS WITH SEVERE COMMUNITY-ACQUIRED PNEUMONIA AT CA MAU GENERAL HOSPITAL IN 2025-2026

Tran Van Nhat1,2, Vo Pham Minh Thu3,4, Huynh Ngoc Linh5,6
1 Cai Nuoc General Hospita
2 Bệnh viện Đa khoa Cái Nước
3 Can Tho University of Medicine and Pharmacy
4 Trường Đại học Y Dược Cần Thơ
5 Ca Mau Medical College
6 Trường Cao đẳng Y tế Cà Mau
DOI: 10.52163/yhc.v67i5.5171
29 Views
11 Downloads
Keywords
Severe community-acquired pneumonia, empirical antibiotic therapy, 28-day mortality.
Abstract

Objectives: To evaluate the outcomes of empirical antibiotic therapy and to analyze the impact of antibiotic appropriateness on 28-day mortality in patients with severe community-acquired pneumonia.

Subjects and methods: A prospective cohort study was conducted on 120 patients aged ≥ 18 years diagnosed with severe community-acquired pneumonia according to Ministry of Health criteria. Patients were treated at Ca Mau General Hospital from July 2025 to February 2026. The appropriateness of empirical antibiotic regimens was determined based on treatment guidelines and antimicrobial susceptibility results. Patients were followed for 28 days.

Results: The mean age was 68.1 ± 14.8 years; 56.7% were male and 64.2% had comorbidities. Appropriate empirical antibiotic therapy was administered in 73.3% of cases. The 28-day mortality rate was 17.5%. Mortality was significantly higher in patients receiving inappropriate empirical antibiotics compared with those receiving appropriate therapy (37.5% vs. 10.2%; p = 0.002). Multivariable analysis showed that inappropriate empirical antibiotic use (OR = 4.1; 95% CI: 1.5-11.2; p < 0.01) and non-susceptible antimicrobial patterns (OR = 2.8; 95% CI: 1.1-7.2; p < 0.05) were independently associated with increased 28-day mortality.

Conclusion: Both the appropriateness of empirical antibiotic therapy and non-susceptible antimicrobial patterns are independently associated with 28-day mortality in patients with severe community-acquired pneumonia.

References
[1]
Bộ Y tế. Quyết định số 4815/QĐ-BYT, ngày 20 tháng 11 năm 2020, về việc ban hành tài liệu chuyên môn “Hướng dẫn chẩn đoán và điều trị viêm phổi mắc phải cộng đồng ở người lớn”. Google Scholar
[2]
Metlay J.P, Waterer G.W, Long A.C et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med, 2019, 200 (7): e45-e67. doi: 10.1164/rccm.201908-1581ST. Google Scholar
[3]
Postma D.F, van Werkhoven C.H, van Elden L.J.R et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med, 2015, 372 (14): 1312-1323. doi: 10.1056/NEJMoa1406330. Google Scholar
[4]
Garin N, Genné D, Carballo S et al. β-lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized clinical trial. JAMA Intern Med, 2014, 174 (12): 1894-1901. doi: 10.1001/jamainternmed.2014.4887. Google Scholar
[5]
Nguyễn Kỳ Nam. Đánh giá sử dụng kháng sinh trong điều trị viêm phổi cộng đồng tại Bệnh viện Trường Đại học Y Dược Cần Thơ. Tạp chí Y học thành phố Hồ Chí Minh, 2021, 25 (3): 45-52. Google Scholar
[6]
Niederman M.S, Torres A. Severe community-acquired pneumonia. Eur Respir Rev, 2022, 31 (166): 220123. doi: 10.1183/16000617.0123-2022. Google Scholar
[7]
Restrepo M.I, Reyes L.F. Pneumonia as a cardiovascular disease. Chest, 2020, 157 (4): 1046-1056. doi: 10.1016/j.chest.2019.10.005. Google Scholar
[8]
Bộ Y tế. Báo cáo giám sát kháng kháng sinh tại Việt Nam 2020, Hà Nội, 2023. Google Scholar
[9]
Kumar A, Roberts D, Wood K.E et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med, 2006, 34 (6): 1589-1596. doi: 10.1097/01.CCM.0000217961.75225.E9. Google Scholar
[10]
Gattarello S, Ranzani O.T, Ferrer M et al. Impact of inappropriate empirical antibiotic therapy on outcomes in severe community-acquired pneumonia: a multicentre study. Clin Infect Dis, 2024, 78 (4): e123-e131. Google Scholar